Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias
| Status: | Terminated |
|---|---|
| Conditions: | Pneumonia, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | April 2010 |
| End Date: | February 2013 |
Genetics, Genomics, and Proteomics of Idiopathic Interstitial Pneumonias: Identification of Susceptibility Genes, Biomarkers, and Molecular Phenotyping
We hypothesize that a peripheral blood biomarker or biological signature (gene or protein
expression pattern) of idiopathic interstitial pneumonias (IIPs) will simplify and improve
the accuracy of diagnosis of IIP and diagnose individuals at an earlier, more treatable,
stage of their disease.
expression pattern) of idiopathic interstitial pneumonias (IIPs) will simplify and improve
the accuracy of diagnosis of IIP and diagnose individuals at an earlier, more treatable,
stage of their disease.
The Broad Challenge Area addressed in this proposal is (03) Biomarker Discovery and
Validation, and the Specific Challenge Topic is 03-HL-101 (Identify and validate clinically
relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood,
vascular, cardiac, and respiratory tract dysfunction). Idiopathic interstitial pneumonia
(IIP) is a lung disease(s) that primarily affects the elderly, but is present in all age
groups. IIP causes respiratory insufficiency and is often fatal. In about half of the
patients, the diagnosis requires an invasive lung biopsy which can cause complications, and
is not always accurate.
The current diagnostic tools for IIP are inadequate. In addition to inaccurate diagnosis,
they are very costly, and often result in delayed diagnosis and treatment. The challenge(s)
we intend to address in this proposal is to improve the accurate and early diagnosis of
idiopathic interstitial lung pneumonia (IIP), and to improve the ability to differentiate
the subtypes of idiopathic interstitial pneumonias (IIPs) by developing peripheral blood
biomarkers.
Validation, and the Specific Challenge Topic is 03-HL-101 (Identify and validate clinically
relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood,
vascular, cardiac, and respiratory tract dysfunction). Idiopathic interstitial pneumonia
(IIP) is a lung disease(s) that primarily affects the elderly, but is present in all age
groups. IIP causes respiratory insufficiency and is often fatal. In about half of the
patients, the diagnosis requires an invasive lung biopsy which can cause complications, and
is not always accurate.
The current diagnostic tools for IIP are inadequate. In addition to inaccurate diagnosis,
they are very costly, and often result in delayed diagnosis and treatment. The challenge(s)
we intend to address in this proposal is to improve the accurate and early diagnosis of
idiopathic interstitial lung pneumonia (IIP), and to improve the ability to differentiate
the subtypes of idiopathic interstitial pneumonias (IIPs) by developing peripheral blood
biomarkers.
Inclusion Criteria:
- Sporadic cases of Idiopathic Pulmonary Fibrosis and other types of Idiopathic
Interstitial Pneumonias.
- Family members ( with or without clinical disease) with a family history of pulmonary
fibrosis.
Exclusion Criteria:
We found this trial at
2
sites
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
National Jewish Health National Jewish Health is known worldwide for treatment of patients with respiratory,...
Click here to add this to my saved trials